A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Pat
This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multip
| Condition(s) | Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Multiple Myeloma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cogni |
| Who can participate | Inclusion Criteria: * Patients \>= 18 years of age * Diagnosed with relapsed/refractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL) * Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment * English literacy Exclusion Criteria: * Patients expected to live \< 6 months * Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery * Confirmed Alzheimer disease or other dementia * Previous central nervous system (CNS) radiation * Active intrathecal therapy at time of enrollment |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
| Locations | Columbus, Ohio, United States |
| Start date | 2026-04-28 |
| NCT ID | NCT07609030 |
| Official listing | https://clinicaltrials.gov/study/NCT07609030 |